Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database.
Residual pain and harm minimisation still areas of need.
@RheumNow #ACR22 ABST0925
https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY
Links:
Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheu…
https://tinyurl.com/442br4bv
13-11-2022